Wednesday, April 29
8:00 – 5:00 pm
7:45 – 8:30 am
Curated Coffee with Innovators
9:00 – 12:00 pm
8:30 – 9:30 am
Technology meets Neuroscience: A Vision of the Future of Brain Optimization
A fundamental challenge of our global healthcare system is the development and deployment of effective treatments to enhance cognition in those suffering from diverse psychiatric and neurological conditions. Dr. Gazzaley will describe an approach to use closed-loop video games coupled with innovations in virtual reality, motion capture, physiological recordings, non-invasive brain stimulation and artificial intelligence to achieve cognitive enhancement in clinical patients, as well healthy children and older adults.
Keynote: Adam Gazzaley, Founder & Executive Director, Neuroscape
9:30 – 9:45 am
9:45 – 10:30 am
Futurescaping of Oncology
Emerging Technologies that could Reshape the Therapeutic Landscape
Jeff Bockman, EVP, Head of Oncology Practice, Cello Health BioConsulting
William Ho, President & CEO, Incysus Therapeutics Inc.
Jacob Becraft, Co-founder & CEO, Strand Therapeutics
10:30 – 11:15 am
Bioethics & Controversial Trends
Hacking medical devices, privacy, bio-hacking, patients self-diagnosing, self-augmentation with technology, access to longevity, bioterrorism, tech developments vs. evidence-based medicine will be discussed in this cutting edge sessions.
Jeremy Abbate, VP & Publisher, Scientific American
Jennifer Miller, Assistant Professor, Yale University School of Medicine
MaryAnne Rizk, Senior Vice President, Digital R&D Strategy, IQVIA (Invited)
11:15 – 12:00 pm
Drugging the Undruggable
It is estimated that up to 85% of the human proteome is currently “undruggable.” These proteins lack easy-to-find pockets where therapeutics can bind. A wave of biotech companies with new technologies have arrived to tackle the problem to overcome the most elusive drug targets.
Jeff Livingstone, Global Head, Business Development, Immunai
David Rooklin, CEO & Co-Founder, Redesign Science
Sotirios Stergiopoulos, President, CEO & Founder, A2A Pharma (Invited)
12:00 – 1:45 pm
Lunch Plenary Session
The Dinosaurs Didn’t See the Asteroid: Does Biopharma?
While a seemingly ubiquitous cliché, “disruption” is still the driving seismic force that reshapes industries and profoundly changes how consumers engage with products and services. How and when will the technological, digital and social trends driving tomorrow’s health innovation upend the current categories of biopharma, medical devices and diagnostics? And can these legacy industries adapt in time to stave it off?
Melinda Decker, Digital Health Advisor
Chihiro Hosoya, Head of Venture Management & Business Development, Astellas Rx+Business Accelerator
Tim M. Jaeger, Global Head Diagnostics Information Solutions, Roche (Invited)
Ajit Singh, Managing Director & General Partner, Artiman Ventures
2:00 – 4:00 pm
2:00 – 2:45 pm
New Approaches to Pain
Millions of adults in the US live with chronic pain. Opioids are still the most effective treatment for severe pain but they come with side-affects and indeed, are abused. In fact, opioid addiction is a leading health crisis across the US. Both biopharma and digital medicine companies are developing non-opioid/addictive alternatives to address this need.
Jared Hopkins, Reporter, Wall Street Journal (Invited)
Shai Gozani, CEO, NeuroMetrix (Invited)
Michelle James, Assistant Professor, Department of Radiology and Department of Neurology & Neurological Sciences, Stanford University (Invited)
Lincoln Nguyen, CEO, Karuna Labs
Josh Sackman, President & Co-founder, appliedVR
Paula Searcy, Director of Business Development, Sana Health
R. Scott Shively, CEO, Neumentum, Inc. (Invited)
2:45 – 3:30 pm
Inflammasomes: Turning-Off Disease Causing Immune Response
Turning off or mediating inflammation.
3:30 – 4:15 pm
“Toward a World Without Disease"
William N. Hait, Global Head, Johnson & Johnson External Innovation
4:15 – 5:00 pm
Closing Plenary Session
New Kids on the Block: Funders of the Future
As the healthcare and bioscience industries evolve, investment sources are increasingly coming from non-traditional places: foundations, accelerators, crowd-sourcing, venture arms of non-profit entities and others. How is this new funding landscape creating opportunities in the US and abroad? How will it affect the larger innovation ecosystem and the players in this space in the years to come?
Kimberly Ha, CEO & founder, KKH Advisors
Jeanne Cunicelli, Executive Vice President, UPMC Enterprises (Invited)
Emi Gonzalez, Principal, Social Starts & Joyance Partners